Galmed Pharmaceuticals Ltd. Daily Stock Analysis

Daily Stock Analysis, GLMD, Galmed Pharmaceuticals Ltd, priceseries

Galmed Pharmaceuticals Ltd. Daily Stock Analysis
Stock Information
Open
1.32
Close
1.34
High
1.38
Low
1.32
Previous Close
1.34
Daily Price Gain
0.00
YTD High
2.18
YTD High Date
Jan 4, 2022
YTD Low
1.31
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.73
YTD Gain
-35.27%
52 Week High
4.08
52 Week High Date
Jun 7, 2021
52 Week Low
1.31
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-2.19
52 Week Gain
-62.04%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
4.30
Mar 7. 2017
4.76
7 Trading Days
10.73%
Link
LONG
Apr 27. 2017
5.14
May 1. 2017
5.46
2 Trading Days
6.23%
Link
LONG
Jun 13. 2017
5.16
Jun 22. 2017
5.87
7 Trading Days
13.84%
Link
LONG
Jul 21. 2017
6.69
Jul 31. 2017
7.11
6 Trading Days
6.23%
Link
LONG
Sep 18. 2017
7.98
Oct 3. 2017
8.73
11 Trading Days
9.34%
Link
LONG
Dec 28. 2017
8.73
Jan 16. 2018
10.46
11 Trading Days
19.84%
Link
LONG
May 31. 2018
6.31
Jun 8. 2018
6.86
6 Trading Days
8.64%
Link
LONG
Jun 11. 2018
7.00
Jun 25. 2018
13.03
10 Trading Days
86.15%
Link
LONG
Jul 12. 2018
12.77
Jul 26. 2018
14.31
10 Trading Days
12.09%
Link
LONG
Apr 7. 2020
3.42
Apr 23. 2020
4.33
11 Trading Days
26.50%
Link
LONG
May 11. 2020
4.58
May 12. 2020
4.92
1 Trading Days
7.31%
Link
LONG
Nov 13. 2020
3.39
Dec 4. 2020
3.71
14 Trading Days
9.41%
Link
LONG
Feb 1. 2021
3.98
Feb 16. 2021
4.45
10 Trading Days
11.84%
Link
LONG
Jun 3. 2021
2.74
Jun 15. 2021
3.22
8 Trading Days
17.48%
Link
LONG
Aug 23. 2021
2.88
Sep 3. 2021
3.06
9 Trading Days
6.28%
Link
Company Information
Stock Symbol
GLMD
Exchange
NasdaqCM
Company URL
http://www.galmedpharma.com
Company Phone
97236938448
CEO
Allen Baharaff
Headquarters
-
Business Address
16 ZE'EV TYOMKIN ST. (4TH FL.), TEL AVIV, ISRAEL 6578317
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001595353
About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. The Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading